Mixed In Key Serial Code Macif BleuPatent US2. Nicotine Immunonanotherapeutics. RELATED APPLICATIONS0. This application is a continuation in part of PCT Application Serial No. PCTUS0. 80. 11,9. SrxdSCbXXQ/V4__nscnnZI/AAAAAAAAozE/FxQ6-DwiW0sRUiv_5z6xiqItfkAzvVnfACKgB/s640/F16%2BWorlds%2B2016%2B-%2BDay%2B3%2Braces%2B%252820-07-2016%2529-5815.jpg' alt='Mixed In Key Serial Code Macif' title='Mixed In Key Serial Code Macif' />Oct. GOVERNMENT SUPPORT0. This invention was made with government support under Grant Nos. Adobe Premiere Pro Cs3 Video Effects Plugins. EB0. 03. 64. 7, AI0. NvlcS' alt='Mixed In Key Serial Code Macif Mon' title='Mixed In Key Serial Code Macif Mon' />Home page About Us Terms Of Use Help Uninstall Contact Us English Espaol Arabic Portugus Deutsch Italiano Franais Dutch Trke. NOTICE Certain statements contained in this Registration Document may relate to objectives of SCOR SE SCOR SE or the Company or of the SCOR Group. The present invention relates to compositions and methods for characterizing, treating and diagnosing cancer. In particular, the present invention provides a cancer. Get Samsung Samsung SlM3370fd SLM3370FD Multifunction ProXpress. Samsung SlM3370fd SLM3370FD Multifunction ProXpress Printer Manual. MacIf the printer. AI0. 69. 25. 9, awarded by the NIH. The government has certain rights in this invention. BACKGROUND OF THE INVENTION0. Many current vaccines against microbial pathogens comprise live attenuated or non virulent strains of the causative microorganisms. Many vaccines comprise killed or otherwise inactivated microorganisms. Other vaccines utilize purified components of pathogen lysates, such as surface carbohydrates or recombinant pathogen derived proteins. Vaccines that utilize live attenuated or inactivated pathogens typically yield a vigorous immune response, but their use has limitations. For example, live vaccine strains can sometimes cause infectious pathologies, especially when administered to immune compromised recipients. Moreover, many pathogens, particularly viruses, undergo continuous rapid mutations in their genome, which allow them to escape immune responses to antigenically distinct vaccine strains. Given the difficulty of vaccine development, many vaccines are in extremely short supply. For example, as of October 2. A vaccine shortages in the United States. In some instances, vaccine shortages occur because not enough manufacturers devote their facilities to vaccine production to keep up with demand. In some cases, vaccine shortages are attributed to low potency of the vaccine, which means a large amount of vaccine product must be administered to each individual in order to achieve a prophylactic effect. For example, some vaccines cannot be administered as an intact organism even if attenuated or killed because they cause infectious pathologies. Instead, such vaccines usually comprise purified pathogen components, which typically leads to a much less potent immune response. Thus, there is a need in the art for systems and methods for producing highly immunogenic, effective vaccines. There is also a need for improved vaccine compositions that can potently induce long lasting immune responses. For the treatment and prevention of infectious diseases, there is a need for improved vaccine compositions that are highly immunogenic but do not cause disease. Smoking of cigarettes, cigars, and pipes is a prevalent problem in the United States and worldwide. Smoking tobacco and smokeless tobacco are rich in nicotine, which is a known addictive substance. Peak levels of nicotine in the blood, about 2. In humans, smoking a cigarette results in arterial nicotine concentrations being 1. Henningfield 1. 99. QlC41f6MM/UwFSxNbH8SI/AAAAAAAAX10/6gbcH74Xd4M/s1600/hobie16worlds2014australiab.jpg' alt='Mixed In Key Serial Code Macif' title='Mixed In Key Serial Code Macif' />Drug Alcohol Depend. This results in a rapid delivery of high arterial concentrations of nicotine to the brain. Once nicotine crosses the blood brain barrier, evidence suggests that it binds to cholinergic receptors. When nicotine binds to these receptors, it can affect normal brain function, by triggering the release of other neurotransmitters, such as dopamine Dopamine is found in the brain in regions involved in emotion, motivation, and feelings of pleasure. It is the release of neurotransmitters, especially dopamine, that is responsible for the tobacco users addiction to nicotine or other intake of nicotine. Nicotine is an alkaloid derived from the tobacco plant that is responsible for smokings psychoactive and addictive effects. Nicotine is formed of two rings linked together by a single bond an aromatic six membered ring pyridine and an aliphatic five membered ring pyrrolidine. The pyrrolidine is N methylated and linked through its carbon 2 to the carbon 3 of pyridine. Thus, the carbon 2 is chiral, and there is virtually free rotation around the single bond linking the two rings. It has been established that the absolute configuration of carbon 2 is S. Thus, the natural configuration of nicotine is S nicotine. Therapies for nicotine addiction have been developed, but are largely ineffective. The two most popular therapies remain the nicotine transdermal patch and nicotine incorporated into chewing gum. These therapies, termed nicotine replacement therapies NRTs, replace the amount of nicotine which the user previously received from smoking and act to wean the user off nicotine. However, certain drawbacks are seen with this type of therapy. Particularly, there is low penetration of nicotine into the bloodstream and therefore an increased desire to smoke. There remains a need in the art to develop improved methods of treating addiction such as addictions to nicotine, cocaine, heroine, alcohol, and other drugs. Ideal methods for treating addiction would, for example, result in minimal withdrawal symptoms, encourage patient compliance by being simple to administer, and result in low relapse rates among patients. SUMMARY OF THE INVENTION0. The present invention provides synthetic nanocarriers for modulating the immune system. The synthetic nanocarriers comprise one or more surfaces, where at least one of the surfaces comprises an immunofeature surface. Optionally the synthetic nanocarriers of the invention further contain one or more of an immunomodulatory agent, an immunostimulatory agent, and a targeting agent also referred to herein as targeting moiety. The immunomodulatory agent induces an immune response in B andor T cells. The immunostimulatory agent helps stimulate the immune system in a manner that can ultimately enhance, suppress, direct, or redirect an immune response. The immunofeature surface recognizes one or more targets associated with antigen presenting cells. The optional targeting agent recognizes one or more targets associated with a particular organ, tissue, cell, andor subcellular locale. The nanocarriers are useful in pharmaceutical preparations and kits for the prophylaxis andor treatment of diseases, disorders, or conditions susceptible to treatment by immune system modulation. Such conditions include those diseases, disorders, or conditions modified by enhancing the immune response specifically or nonspecifically, suppressing the immune response specifically or nonspecifically, or directingredirecting the immune response specifically or nonspecifically. An immunofeature surface, as described in more detail herein, provides for specific targeting of the nanocarriers to antigen presenting cells APCs. In particular, the immunofeature surface provides for high avidity binding of the nanocarriers to APC surfaces. Furthermore, the high avidity binding is specific to APC cells. For example, in some embodiments, nanocarriers of the invention are capable of specifically targeting subcapsular sinus macrophages SCS Mphs. Such nanocarriers accumulate in the subcapsular sinus region of lymph nodes when administered to a subject. In other embodiments, the nanocarriers of the invention are capable of specifically targeting dendritic cells and eliciting a T cell response. In some preferred embodiments, the immunofeature surface provides low affinity, high avidity binding of the nanocarriers to APC surfaces. In some embodiments, nanocarriers comprising an immunofeature surface exhibit specific low affinity high avidity binding to APCs, and do not provide such binding to other types of cells Further details of immunofeature surfaces are provided herein.